• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Mineralys Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/12/25 4:06:28 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLYS alert in real time by email
    mlys-20250812
    false000193341400019334142025-08-122025-08-12

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 12, 2025
    MINERALYS THERAPEUTICS, INC.
    (Exact name of registrant as specified in its charter)
    Delaware001-4161484-1966887
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification No.)
    150 N. Radnor Chester Road, Suite F200
    Radnor, Pennsylvania 19087
    (Address of principal executive offices) (Zip Code)
    (888) 378-6240
    (Registrant’s telephone number, include area code)
    N/A
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.0001 per share
    MLYS
    The Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02 Results of Operations and Financial Condition.
    On August 12, 2025, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.
    Item 9.01. Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit
    No.
    Description
    99.1
    Press Release Issued on August 12, 2025
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Dated: August 12, 2025MINERALYS THERAPEUTICS, INC.
    By:/s/ Adam Levy
    Name:Adam Levy
    Title:Chief Financial Officer and Secretary

    Get the next $MLYS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLYS

    DatePrice TargetRatingAnalyst
    6/11/2025$15.00Hold
    Jefferies
    7/10/2024$30.00Buy
    H.C. Wainwright
    4/2/2024$30.00Buy
    Goldman
    3/7/2023Outperform
    Evercore ISI
    3/7/2023$39.00Buy
    BofA Securities
    3/7/2023$32.00Buy
    Guggenheim
    3/7/2023$27.00Overweight
    Wells Fargo
    3/7/2023$45.00Buy
    Stifel
    More analyst ratings

    $MLYS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Mineralys Therapeutics Inc.

    SCHEDULE 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    8/14/25 4:13:57 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Mineralys Therapeutics Inc.

    SCHEDULE 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    8/14/25 4:05:09 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Mineralys Therapeutics Inc.

    144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    8/13/25 5:21:54 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    – Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD Phase 2 trial successfully achieved statistical significance in reduction of systolic BP and UACR, and demonstrated a favorable safety profile – – Explore-OSA Phase 2 trial in OSA participants with hypertension is ongoing; topline results anticipated in 1H 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to

    8/12/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

    RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2025, after the financial markets close on Tuesday, August 12, 2025. Tuesday, August 12th @ 4:30 p.m. ETDomestic:1-877-704-4453International:1-201-389-0920Conference ID:13754684Webcast:Webcast Link   A live webcast of the conference call may also be found on the "News & E

    8/4/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

    – Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reduction in the pre-defined endpoint spot urine albumin-to-creatinine ratio of 31% (p<0.0001) – – Lorundrostat demonstrated a favorable safety and tolerability profile – – Conference call today at 8:00 a.m. ET – RADNOR, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep

    6/17/25 7:00:00 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    4/25/25 7:01:59 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Samsara Biocapital Gp, Llc bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    3/17/25 9:05:47 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Akkaraju Srinivas bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    3/17/25 9:04:15 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rodman David Malcom exercised 6,349 shares at a strike of $1.08 and sold $146,987 worth of shares (11,365 units at $12.93), decreasing direct ownership by 5% to 92,891 units (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    8/14/25 6:02:58 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO and Secretary Levy Adam Scott sold $1,077,477 worth of shares (73,678 units at $14.62), decreasing direct ownership by 36% to 132,934 units (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    7/30/25 8:12:01 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Congleton Jon sold $230,431 worth of shares (15,884 units at $14.51), decreasing direct ownership by 2% to 846,405 units (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    7/15/25 5:02:38 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Mineralys Therapeutics with a new price target

    Jefferies initiated coverage of Mineralys Therapeutics with a rating of Hold and set a new price target of $15.00

    6/11/25 7:54:20 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Mineralys Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

    7/10/24 7:50:59 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Mineralys Therapeutics with a new price target

    Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

    4/2/24 7:34:24 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Leadership Updates

    Live Leadership Updates

    View All

    Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

    RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer. "With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team. She brings a solid track record of generating value for multiple companies by identify

    1/4/24 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy

    LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch ("Praxis"), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer's Disease, today announced the appointment of Adam Levy to its Board of Directors (the "Board"). Mr. Levy brings executive, financial and operational leadership experience in biopharmaceuticals. "We are excited to have Adam join our Board and support our mission to improve the lives of patients with Alzheimer's Disease," said Sandeep Patil, MD PhD, chief executive officer of Praxis Bioresearch. "Adam brings an impressive

    9/19/23 4:00:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Financials

    Live finance-specific insights

    View All

    Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    – Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD Phase 2 trial successfully achieved statistical significance in reduction of systolic BP and UACR, and demonstrated a favorable safety profile – – Explore-OSA Phase 2 trial in OSA participants with hypertension is ongoing; topline results anticipated in 1H 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to

    8/12/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

    RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2025, after the financial markets close on Tuesday, August 12, 2025. Tuesday, August 12th @ 4:30 p.m. ETDomestic:1-877-704-4453International:1-201-389-0920Conference ID:13754684Webcast:Webcast Link   A live webcast of the conference call may also be found on the "News & E

    8/4/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

    – Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reduction in the pre-defined endpoint spot urine albumin-to-creatinine ratio of 31% (p<0.0001) – – Lorundrostat demonstrated a favorable safety and tolerability profile – – Conference call today at 8:00 a.m. ET – RADNOR, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep

    6/17/25 7:00:00 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:27:48 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:19:46 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:09:56 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care